Furthermore, our observation that selected GATA-3 target genes, including c-Myc, CCR4, IKZF3 and ITK, are therapeutically targetable is noteworthy (Fig. 6G), as improved therapeutic strategies for these lymphomas are clearly needed. This evidence concerns the gene ITK and lymphoma.